The use of hydroxyurea pretreatment in chronic myeloid leukemia in the current tyrosine kinase inhibitor era

• Camille C.B. Kockerols,
• Inge Geelen,
• Mark-David Levin,
• Jeroen J.W.M. Janssen,
• Avinash G. Dinmohamed,
• Mels Hoogendoorn,
• Jan J. Cornelissen,
• Peter E. Westerweel

Affiliations

Camille C.B. Kockerols

Department of Internal Medicine, Hematology, Albert Schweitzer Hospital, Dordrecht

Inge Geelen

Department of Hematology, Erasmus University Medical Center, Rotterdam

Mark-David Levin

Department of Internal Medicine, Hematology, Albert Schweitzer Hospital, Dordrecht

Jeroen J.W.M. Janssen

Department of Hematology, Amsterdam University Medical Center, location VU Medical Center, Amsterdam

Avinash G. Dinmohamed

Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands; Department of Public Health, Erasmus University Medical Center, Rotterdam

Mels Hoogendoorn

Department of Hematology, Medical Center Leeuwarden, Leeuwarden

Jan J. Cornelissen

Department of Hematology, Erasmus University Medical Center, Rotterdam

Peter E. Westerweel

Department of Internal Medicine, Hematology, Albert Schweitzer Hospital, Dordrecht